Transformed Plants Accumulating Terpenes

Joe Chappell  
*University of Kentucky, chappell@uky.edu*

Shuiqin Wu  
*University of Kentucky*

Michel Schalk

Anthony Clark

Follow this and additional works at: [https://uknowledge.uky.edu/pss_patents](https://uknowledge.uky.edu/pss_patents)

Part of the [Plant Sciences Commons](https://uknowledge.uky.edu/pss_patents)

**Recommended Citation**

Chappell, Joe; Wu, Shuiqin; Schalk, Michel; and Clark, Anthony, "Transformed Plants Accumulating Terpenes" (2011). *Plant and Soil Sciences Faculty Patents*. 3.  
[https://uknowledge.uky.edu/pss_patents/3](https://uknowledge.uky.edu/pss_patents/3)

This Patent is brought to you for free and open access by the Plant and Soil Sciences at UKnowledge. It has been accepted for inclusion in Plant and Soil Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
TRANSFORMED PLANTS ACCUMULATING TERPENES

Inventors: Joe Chappell, Lexington, KY (US); Shuqin Wu, Lexington, KY (US); Michel Schalk, Collonges-Sous-Saleve (FR); Anthony Clark, West Windsor, NJ (US)

Assignee: University of Kentucky Research Foundation, Lexington, KY (US)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 681 days.

App. No.: 11/911,660

PCT Filed: Apr. 18, 2006

PCT No.: PCT/IB2006/051198

§ 371 (c)(1), (2), (4) Date: Apr. 25, 2008

PCT Pub. No.: WO2006/111924

PCT Pub. Date: Oct. 26, 2006

Prior Publication Data

Foreign Application Priority Data
Jun. 16, 2005 (EP) 05105281

Int. Cl.
C12N 15/29 (2006.01)
C12N 15/31 (2006.01)
C12N 15/52 (2006.01)
C12N 15/82 (2006.01)

U.S. Cl. 800/288; 800/298; 435/193; 435/320.1

Field of Classification Search None

References Cited
U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS
WO 00/22150 4/2000
WO 02/33060 A2 4/2002
WO 02/064764 A2 8/2002

OTHER PUBLICATIONS

Primary Examiner — Russell Kallis
Attorney, Agent, or Firm — Winston & Strawn LLP

ABSTRACT

The present invention relates to transformed plants with an altered terpene content, preferably over-accumulating a mono- or sesqui-terpene. By transformation of plants with genes encoding terpene synthases (TS), and prenyl transferases (PRT), plants accumulating at least 1000 ng per g of fresh leaf of a specific terpene were obtained. The present invention provides an advantageous system for production of terpenes in that any desired mono- or sesqui-terpene at the choice of the skilled person can be produced in plants. Preferably, the transformed plants contain at least one recombinant plastid targeted TS and PRT.

10 Claims, 20 Drawing Sheets
Figure 1 (A and B)
Figure 1 C

[Graph showing Relative Abundance vs. m/z with peaks at various m/z values and corresponding relative abundances.]

Figure 1 D
Figure 2

Amorpha-4,11-diene

Cubenol

Retention time (min)
Figure 3

![Graph showing Patchoulol (ng/g FW) levels across various time points and treatments.]

Cytosol target

<table>
<thead>
<tr>
<th>hsPTS</th>
<th>FPS-PTS</th>
<th>PTS + FPP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Plastid target

<table>
<thead>
<tr>
<th>tpPTS</th>
<th>tpFPS-PTS</th>
<th>tpPTS + tpFPP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 4

2PTS

5  6  12  14  WT

2tpPTS

6  7  14  15

2PTS+FPP

11  12  13  19  WT

2tpPTS+tpFPP

1  3  8  13

2FPPPPTS

1  2  4  5  WT

2tpFPPPPTS

1  29  33  34

Panel indicates the presence of specific bands corresponding to WT (wild type) and various expression conditions.
Figure 5
Figure 8

Sphl → P-NOS → HPT → CaUTR → attp2 → cm ccdB → attp1 → T-NOS → Sstl → LB

pBDON

Figure 9 A

Ndel → EcoRI → Pcv → TNOS → attB2

Gene 1

pTMON

Figure 9 B

SphI → SgfI → EcoRI → XhoI → XbaI → SpeI → KpnI → SacI → Gene 1 → Tnos → Pca → Gene 2 → Tnos → attB2

pTDUAL
Figure 10 A

Figure 10 B
Figure 11

```

pTHPT
(18)

pTRBP
(19)

pTRBP_HPT
(20)

pBDON
(21)

pBI101 (invitrogen, Carlsbad, CA)
(15)

ccm ccdB
(14)

sp
(13)

```
Figure 13 part II

Gene 1

\( \text{pTVCVST} \)

\( \text{pTDUAL} \)
Figure 15 part I

EcoRI SacI KpnI XbaISphIHindIII

pT7blue

Digested with HindIII
Blunted with T4 polymerase & Selfligated.

EcoRI SacI KpnI XbaISphI

linker

EcoRI/KpnI cut & ligated with linker.

SgfIBamHISpeI NotI Smal KpnI XbaISphI

pLink

XbaISphI

attP

SgfIBamHISpeI NotI Smal KpnIXbaISphI

pLattP

attP

KpnIHindIIIStuIXbaI

Trbcl aadA Prrn

SgfIBamHISpeI NotI Smal KpnI HindIIIStuIXbaISphI

pLattP+aadA+Prnn+Tatp

SgfIBamHISpeI NotI Smal KpnI HindIIIStuIXbaISphI

pLattP+aadA+Prnn

SgfIBamHISpeI NotI Smal KpnI HindIIIStuIXbaISphI

pLattP+aadA

SgfIBamHISpeI NotI Smal KpnI HindIIIStuIXbaISphI

pLattP+aadA+Prnn+Tatp

SgfIBamHISpeI NotI Smal KpnI HindIIIStuIXbaISphI

pLattP+aadA
Figure 15 part II
Figure 15 part III
With transient expression of helper Vector pKO107 or pKO111
TRANSFORMED PLANTS ACCUMULATING TERPENES

TECHNICAL FIELD

The present invention relates to transformed plants over-accumulating a specific mono- or sesquiterpene. The present invention further relates to a transformed plant with an altered content of a specific terpene, a vector comprising at least one nucleotide sequence encoding a prenyl transferase (PRT) and/or a mono- or sesquiterpene synthase (TS), methods for altering the content of specific terpenes in a plant, a method for increasing the content of specific terpenes in a plant, a method of producing a specific terpene and the use of at least one nucleotide sequence for producing plants having an altered terpene content.

BACKGROUND OF THE INVENTION AND PROBLEM TO BE SOLVED

Terpenes and terpenoids are found in most organisms. Their important commercial value, which is constantly increasing, is linked to the diverse range of bioactivities and functionalities encompassed by different terpenes. Accordingly, many vitamins, hormones, insect repellents, drugs, flavors and fragrances are found amongst this very large class of compounds, which all are made starting from units of 5 carbons called isoprene units.

Terpenes can be classified by the number of isoprene units present in their structure: monoterpenes (C₆₋₈), sesquiterpenes (C₁₀₋₁₅), diterpenes (C₂₀), triterpenes (C₃₀), tetraterpenes (C₄₀) and polyterpenes (Cₙ, n equal to or greater than 45 carbons). The plant kingdom contains a high diversity of mono- and sesquiterpenes representing thousands of different structures.

The chemical synthesis of higher terpenes such as sesqui- and diterpenes is very complex and environmentally acceptable processes for their preparation have not yet been realized. Therefore, it is a first objective of the present invention to provide methods for efficiently producing or accumulating specific terpenes while avoiding multiple-step chemical synthesis.

Studies on the biosynthetic pathway of terpenes revealed that the common C₅-precuror to all terpenes is isopentenyl diphosphate (IPP). Two distinct pathways for IPP biosynthesis coexist in the plants. The mevalonate pathway (MVA) is found in the cytosol in association with the endoplasmic reticulum and the non-mevalonate pathway, also called deoxyxylulose or methyl-D-erythritol phosphate pathway (DOXP/MEP) is found in the plastids of higher plants. The starting products, the enzymes involved and the catalyzed reactions are different in both pathways, and, in the cells of higher plants they operate in parallel and complement each other. Accordingly, the MVA pathway in the cytoplasm is responsible for the biosynthesis of sterols, sesquiterpenes, and polyterpenes, whereas the plastid (MEP pathway) provides C₅-units for the synthesis of monoterpenes, diterpenes, for example kaurene (C₂₀), and polyterpenes, for example carotenoids (C₄₀) and plastoquinone-9 (C₄₅).

Following the synthesis of IPP, it is repetitively condensed by prenyl transferases (PRT) to form the acyclic prenyl diphosphate terpene precursors for each class of terpenes, that is, geranyl-diphosphate (GPP) for the monoterpenes, farnesyl-diphosphate (FPP) for the sesquiterpenes, geranylgeranyl-diphosphate (GGPP) for the diterpenes. These precursors in turn serve as substrate for the terpene synthases or cyclases, which are specific for each class of terpene, e.g. monoterpene, sesquiterpene or diterpene synthases. Terpene synthases can catalyze complex multiple step cyclizations to form the large diversity of carbon skeleton of the terpene compounds.

Attempts have been made to isolate specific terpene synthases and WO 2004/031376 reports the isolation of the genes encoding culebrol, valencene and germacrene synthases. When E. coli cells were transformed with plasmids containing these genes, the corresponding fragrance compounds could be found in the cultivating medium. Generally, in view prior art concerned with heterologous expression of terpene synthases, it is an objective to provide means and methods for accumulating specific terpenes in still higher amounts.

In U.S. Pat. No. 5,589,619, U.S. Pat. No. 5,365,017, U.S. Pat. No. 5,349,126 and U.S. Pat. No. 5,349,126 processes for increasing squalene and sterol accumulation in transgenic plants are disclosed. These references, however, are silent as to how the accumulation of other classes of terpenes, such as mono-sesqui- and diterpenes could be increased.

The preparation of transgenic plants is also the subject of U.S. Pat. No. 6,841,717, which relates to genes associated with the MEP-pathway. This reference teaches a DNA molecule encoding an HMBPP-Synthase (GCPE protein), which was linked to a chloroplast transit peptide and was thus used to produce a transgenic plant. While this reference deals with the accumulation of tocopherol substrates, it is silent how other terpene compounds can effectively be accumulated.

In U.S. Pat. No. 6,653,530 a method for increasing carotenoid production in seed is disclosed, in which a host plant is transformed with nucleic acid sequence of Erwinia uredora encoding a phytene synthase.

WO 00/22150 discloses methods creating or enhancing resistance to insects in plants by expressing the monoterpenes synthases limonene-, carveol and S-linool synthases in plants transformed with nucleotide sequences encoding these enzymes.

WO 02/33060 A2 discloses nucleic acid sequences and methods for producing plants and seeds having altered tocopherol content and compositions.

In WO 91/13078 DNA sequences encoding various enzymes of Erwinia herbicola are disclosed. Transformed host organisms producing GGPP and various carotenoids are also mentioned.

EP 1 063 297 provides cDNA sequences coding for farnesyl diphosphate synthase and transgenic plants expressing heterologous farnesyl diphosphate synthase.

WO 02/064764 discloses isolated or recombinant nucleic acid sequences capable of synthesizing a monoterpenoid linalool and/or a sesquiterpene nerolidol when contacted with the respective precursor. In example 11, the difficulty of producing sesquiterpenes in transgenic plants is acknowledged, and no concrete results in this respect are presented.

Similarly, in a publication of Aharoni et al. “Terpenoid Metabolism in Wild-Type and Transgenic Arabidopsis Plants”, the Plant cell, Vol. 15, 2866-2884, only very low levels of nerolidol were synthesized by linalool/nerolidol synthase targeted to the plastids.

The present inventors address the problem of producing or accumulating a specific, selected terpene. Preferably, a method is provided, which is suitable to produce not only a pre-determined, but any terpene of interest. The objective is thus to provide a system which allows, for example, the accumulation of any of the above-indicated sesquiterpenes, such as culebrol, valencene, germacrene, patchouliol, but which is also suitable to accumulate other terpenes. This problem has so far not been solved by the prior art, the latter basically suggesting recombinant organisms having modified properties in the MVA or MEP pathway, and observing that certain terpene end products get accumulated.
A further objective of the present invention is to provide means for generating any selected terpene, preferably a sesqui-terpene, in a stereochemically pure form and with a reliable and cost effective production platform.

An important problem addressed by the present inventors is the increased accumulation of a selected terpene, preferably a sesqui-terpene, in plants. In the prior art, yields of a maximum of about 10 μg terpene per g fresh weight plant material are reported. In particular with respect to sesqui-terpenes, accumulation remains particularly low, in general in the order of micro-grams or below. It is thus an objective of the present invention to provide a possibility of accumulating more significant amounts of any terpene at the choice of the skilled person in a plant, and in particular of a sesqui-terpene. Preferably, the plant can easily be cultivated. It is further objective to accumulate the terpene in plant organs that provide a high biomass with respect to the total weight of the adult plant.

Another objective of the present invention is to provide plants accumulating sufficient amounts of terpenes for inhibiting growth of plant pathogens and attack by herbivores.

SUMMARY OF THE INVENTION

Remarkably, the present inventors were able to transform organisms with genes encoding a farnesyl diposphate synthase (FPS) and a specific mono- or sesqui-terpene synthase targeted to the plastids of the plant and obtained high yield of the terpene that is synthesized by the terpene synthase (TS).

For the first time, enzymes of the isoprenoid biosynthetic pathway typically present in the cytosol could be directed to another cell compartment, the plastid, and, surprisingly, the amount of selected terpene compounds could be increased by exploiting precursors of a different pathway. An important advantage of the present invention is that any desired terpene can be accumulated in any plant, if the nucleotide sequence encoding the synthase of the selected terpene is known or susceptible to be isolated. This is possible by targeting to the plastids of a plant at least two gene products, that is a TS and the enzyme capable of synthesising the direct precursor for the TS, a prenyl transferase (PRT).

Accordingly, the present invention provides, in a first aspect, a transformed plant over-accumulating a specific terpene, preferably a mono- or sesqui-terpene.

In a further aspect, the present invention provides a transformed plant with an altered content of a specific terpene, said transformed plant comprising structural genes comprising at least one nucleotide sequence encoding a prenyltransferase (PRT) and a terpene synthase (TS) targeted to the plastids of the plant.

In another aspect, the present invention provides a transformed plant accumulating a sesqui-terpene, which is transformed to comprise at least one nucleotide sequence encoding a farnesyl diposphate synthase (FPS) and a sesqui-terpene synthase targeted to the plastid of the plant.

In a further aspect, the present invention provides a vector comprising at least one nucleotide sequence encoding a PRT and/or a TS, or a fusion protein of a PRT and a TS, said nucleotide sequence further comprising a plastid targeting sequence linked in frame to the nucleotide sequence encoding the PRT, the TS, and/or the fusion protein.

In still further aspects, the present invention provides methods for altering the content of specific terpenes in a plant and for increasing the content of specific terpenes in a plant, the methods comprising the steps of transforming plant material with at least one DNA construct comprising at least one nucleotide sequence encoding a farnesyl diposphate synthase, FPS or, if the terpene is a monoterpene, a geranyldiposphate synthase, and a sesqui-terpene synthase, or a monoterpene synthase, respectively, and, regenerating the transformed plant from the transformed plant material.

In still other aspects, the present invention provides a method of producing a specific terpene, the method comprising the step of isolating the terpene from the plant according to the invention, and, the use of at least one nucleotide sequence encoding a plastid targeted functional PRT and/or TS for producing plants having an altered terpene content.

The present invention also relates to a method of producing a sesqui-terpene, the method comprising the step of cultivating the plant of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows GC-MS analysis of a control tobacco line (WT) and one transformed with a construct comprising plastid targeted genes encoding a sesqui-terpene (patchouliol) synthase and a farnesyl diposphate synthase (fpsTPS4+fpsTPS). Peak 12 in chromatogram A is analysed by MS in part C and could be identified as patchouliol by comparison to authentic patchouliol (D). Peak 3 was used as an internal standard (3-α-cedrene).

FIG. 2 shows GC-MS analysis of a control tobacco line (WT) and one transformed with a construct comprising plastid targeted genes encoding another sesqui-terpene (amorph-4,11-diene) synthase and a farnesyl diposphate synthase (fpsTPS4+fpsTPS). The main peak shows accumulation of amorph-4,11-diene in transformed plants.

FIG. 3 shows patchouliol content in leaves of plants transformed with different constructs (see detail FIG. 2). The comparison reveals that high yields of patchouliol (>10,000 ng/g of fresh leaf FW) were accumulated in tobacco plants transformed with plastid targeted PTPS and FPS, be it in the form of distinct gene products or in the form of a fusion protein. Cytosol targeted constructs remained below 2000 ng/g FW.

FIG. 4 quantitatively shows the mRNA expression levels in regenerated transgenic plant lines overexpressing a farnesyl diposphate synthase (FPS), a sesqui-terpene (patchouliol) synthase (PTS), or both.

FIG. 5 shows Expression levels and processing of the patchouliol synthase (PTS) and farnesyl diposphate synthase (FPS) proteins in transgenic plants as measured immunodetection.

FIG. 6 shows predicted 13C-labeling patterns in patchouliol bio-synthesised through the MEP or MVA pathway in seedlings grown on [1,13C]-glucose.

FIG. 7 compares MS parent ions for patchouliol synthesised by plants fed 13C-glucose (upper panel), versus synthesis from 13C-glucose by plants engineered for cytosolic (middle) or plastidic (bottom) biosynthesis.

FIG. 8 shows the organisation of a vector ("pBDON") suitable for A. tumefaciens-mediated transformation of plants, in which the region between the attp2 and the attp1 sequence (cm ccdB) may in vitro and site-specifically be recombined to harbour a TS, and/or PRT targeted to the plastid of the plant. The vector comprises border regions for transformation of plants, promoters, terminators, and the attp1/2 recombination sequences, as discussed in further detail in the examples.

FIGS. 9 A and 9 B show helper vectors ("pTMON" and "pTDUAL") comprising, between the attp2 and the attp1 sequence, one or two structural genes, respectively, to be inserted by site-specific recombination into the vector pBDON of FIG. 6. Part A shows the helper vector suitable to insert one gene at a time into the pBDON vector, while part B
The present invention relates to a transformed plant accumulating a specific mono-, sesquiterpene. The invention also relates to transformed plants with an altered content of a specific terpene, the plant comprising structural genes targeted to the plastids of the plant.

A "transformed plant", for the purpose of the present invention, is a plant, which was subjected to genetic engineering. A "transformed plant", includes asexually (vegetative) and sexually derived material from an individual plant that has been transformed. For example, plants obtained by crossing of a plant having individually been transformed with an untransformed plant 1 is encompassed by the present invention, if the progeny contains at least a nucleotide sequence encoding a PRT and a terpene synthase targeted to the plastid of the plant, according to the invention. The plant may be any plant, preferably, it is a plant which is suitable to be transformed according to the present invention. Preferably, the plant is a plant, which naturally produces high amounts of terpenes. For example, the plant is selected from the family of Solanaceae, Poaceae or Lamiaeae. For example, the plant is selected from the genus Nicotiana, Solanum, Sorghum, Arabidopsis, Medicago (alfalfa), Gossypium (cotton), Brassica (rapeseed). Preferably, the plant belongs to the species of Nicotiana tabacum.

While the present invention is preferably related to plants, its concepts can equally well be used with other organelle-containing organisms. For example, the present invention also applies to algae and fungi. Preferably, it applies to plastid-containing organisms such as algae and plants.

The terms "altered content of a specific terpene" or "accumulating a specific terpene" means the content of a specific terpene of a plant transformed according to the present invention is higher than the content of the same terpene in the same plant not so transformed. The invention thus covers two main situations: First, the invention relates to plants, the wild-type of which does not produce the terpene of specific interest. By transformation according to the invention, these plants will accumulate the terpene of interest and thus have an altered content of the specific terpene. According to another situation encompassed by the invention, a plant already produces the terpene of interest. By transformation, the plant will produce more of the specific terpene and thus have an altered terpene content.

Similarly, the term "accumulating" or "over-accumulating" refers to a higher content of a specific terpene in a transformed plant if compared to the same plant not so transformed.

Accordingly, the term "expression" or "over-expression" of a PRT and/or a TS gene refers to plants having a higher content of PRT and/or TS DNA in any plant organs, for example leaves, than compared to a control, non-transformed plant.

A "terpene", is a hydrocarbon based on or composed of isoprene units (C₅H₈), which may be acyclic or cyclic.

As used herein, a "monoterpe" is a terpene based on a C₁₀ structure and includes monoterpenes derivatives. Examples are menthol, limonene, α-pinene, β-pinene, S-linalool, just to mention specific examples for illustration.

As used herein, a "sesquiterpene" is a terpene based on a C₁₅ structure. Examples are cyclosativene, cyclocopancamphene, cyclocopancamphenol epimers, cyclocopancamphenal epimers, cyclocopancamphenic acid epimers, cis-α-bergamotene, trans-α-bergamotene, (+)-epi-β-santalene, β-bisabolene, and trans-γ-bisabolene.

The terms "terpene", "monoterpe", and "sesquiterpene", for the purpose of the present invention, also includes terpene derivatives, such as terpenoids, which are terpene derivatives including molecules that have undergone one or more steps of functionalization such as hydroxylation, isomerizations, oxidation-reduction, dimethylation, or acylation, for example.

Within the context of this specification the word "comprises" is taken to mean "includes, among other things": It is not intended to be construed as "consists only of".

In a preferred embodiment, the plant of the present invention is transformed to comprise a structural gene comprising a nucleotide sequence encoding a prenyltransferase (PRT) targeted to the plastid of the plant.

According to another preferred embodiment, the plant of the present invention is transformed to comprise a structural gene comprising a nucleotide sequence encoding a terpene synthase (TS) targeted to the plastid of the plant.

The term "targeted to the plastids of the plant" refers to the fact that the PRT and/or the TS will be present in the plastids. These proteins may be targeted to the plastids by nuclear transformation with genes comprising plastid-targeting sequences resulting in gene products being actively transported into the plastids by the plant cell. Another possibility of targeting proteins to the plastids is by transforming the plastid genome directly, in case of which plastid-targeting sequences may no longer be necessary, for example. The plants of the present invention are preferably transformed to comprise genes encoding a PRT and a specific TS targeted to the plastids of the plant cell.

Preferably, the plants of the present invention express PRT and/or TS. Preferably, the plants over-express PRT and/or TS. Expression of PRT or TS is preferably determined by RNA extraction and quantitative RT-PCR analysis following the protocol given in the examples.

Prenyl transferases (PRT), also called poly-prenyl diphosphate synthases or poly-prenyl pyrophosphate synthases are enzymes that catalyse the alkylation steps involving dimethylallyl diphosphate (DMAPP) and one or more IPP residues, for
example farnesyl diphosphate (FPP), geranyl diphosphate (GPP), geranylergeranyl diphosphate (GGPP), or others. The term PRT also includes one or several distinct enzymes capable of catalysing one or a sequence of reactions leading to the polypropenyl diphosphate precursor for the various terpenoid families. Therefore, at least one nucleotide sequence encoding a PRT, for the purpose of the present invention, encompasses sequences encoding for polypeptides having quaternary structures comprising homo- and hetero mixtures of mono-, di-, tri-, tetra-, and ologomeric proteins. In particular, the PRT may be a monomer, a hetero- and/or a homodimer. The geranyl diphosphate synthase from oil glands of peppermint (Mentha piperita) may serve as an example for the complex genetic organisation of certain PRTs encompassed by the present invention, as this enzyme has been purified and was revealed to be a heterodimer, with both subunits required to produce GPP from IPP and DMAPP precursors.

Preferably, PRTs encompass enzymes classified under EC number EC 2.5.1, for example. In a preferred embodiment, the at least one nucleotide sequence encoding a PRT encodes one or more proteins having the activity of a geranyl-diphosphate (GPP) synthase, and/or a farnesyl-diphosphate (FPP) synthase. GPP and FPP are the precursors for mono-, and sesquiterpenes, respectively.

Geranyl-diphosphate synthases (GDS), also called dimethylallyl-transtrnferases, are examples for PRTs.

According to a preferred embodiment, the PRT is a farnesyl diphosphate synthase (FPS). FPSs are enzymes that catalyse, for example, the condensations of geranyl diphosphate (GPP) with IPP to give farnesyl diphosphate. Preferably, the FPS is capable of catalysing the sequential condensation of isopentenyl diphosphate (IPP) with the allylic diphosphates, dimethylallyl diphosphate (DMAPP), and then with the resultant geranyl diphosphate (GPP) to the ultimate product farnesyl diphosphate. Preferably, the PRT present in the transformed plant is isolated from a species different from the transformed plant. According to a preferred embodiment, the PRT is a non-plant PRT. Preferably, the PRT is an animal or fungal PRT, more preferably an animal PRT. Preferably, the PRT vertebrate, more preferably from a bird. Preferably, the PRT is a non-plant farnesyl diphosphate synthase.

For the purpose of the present invention, the transformed plant preferably comprises genes encoding a specific TS and the PRT capable of synthesising the direct precursor of the specific TS as indicated above. For example, a plastid targeted sesquiterpene synthase and a plastid targeted FPS. This is a particularly preferred embodiment of the present invention, because it utilises the MEP pathway for producing sesquiterpenes, which has previously not been demonstrated. As another example, the plant is transformed to comprises genes encoding a plastid targeted GDS and a plastid targeted monoterpene synthase.

A large number of nucleotide sequences encoding PRTs isolated from various organisms are readily available to the skilled person and can be downloaded from public databases. It is an important advantage of the present invention that the nucleotide sequence of any PRTs capable of synthesising the precursor of any corresponding TS may be interchangeably employed in the plants of the present invention.

Publicly available databases suitable for obtaining nucleotide sequences encoding PRTs or TS are, for example, the database of the European Bioinformatics Institute, (http://www.ebi.ac.uk/swissprot/index.html), the EXPASY database (http://www.expasy.org/enzyme/), the NCBI database (http://www.ncbi.nlm.nih.gov) and many others. For the mere purpose of illustrating the many possibilities of FPSs available to the skilled person that could be used for the purpose of the present invention, one could cite a geranyl diphosphate synthase isolated from Ips pini (NCBI Accession number: AY 955808.1), a farnesyl diphosphate synthase isolated from Vibrio fischeri (NCBI AN: YP 203660), and an avian farnesyl diphosphate synthase reported by Tarshis et al. (1994). Of course, any other PRT could be selected from any database.

TS are enzymes that catalyse the formation of a mono- or sesquiterpene from a given precursor compound. An important advantage of the present invention is the exchangeability of the specific terpene synthase. Depending on the particular sesquiterpene that the skilled person is interested in, any corresponding TS can be selected and the nucleotide sequence encoding it can be used for transforming the plant of the invention.

The term “specific” or “selected” terpene, TS or PRT refers to a TS or PRT at the choice of the skilled person. Depending on the “specific” terpene of interest, the nucleotide sequences encoding the PRT and the TS that are capable of synthesising the respective precursor and the terpene of interest are used to prepare the transformed plants. Preferably, the nucleotide sequence encoding the specific TS or PRT, which may be any TS or PRT, is readily available or can be isolated by the skilled person. For example, a “specific” terpene may be a compound having desirable properties as a fragrance, a flavor, a medicinal compound, a vitamin, a insect control agent, a plant control agent, just to mention a few, and may be selected by the skilled person due to any of these properties. The present invention then provides a versatile system that allows for the production or accumulation of the very terpene of interest in plants.

Preferably, the specific TS is a terpene synthase which utilizes any of GPP and/or FPP as an intermediate or precursor up-stream in the terpene biosynthetic pathway in which it naturally occurs. In this case, the carbon flux is more extensively directed towards the accumulation of the specific terpene synthesised by the TS. For example, the TS has farnesyl diphosphate as its direct substrate.

In an embodiment, the TS of the present invention is preferably selected from the group consisting of a monoterpene and a sesquiterpene synthase. Any terpene synthase may be used for the purpose of the present invention. Examples of monoterpene synthases with available sequences are the limonene synthase (LS), (Ohara et al, 2003), S-linalool synthase (LIS), (Lucker et al 2001).

Genes or nucleotide sequences encoding terpene synthases isolated from various organisms can readily be downloaded from publicly accessible databases (see above for PRTs) and are also disclosed in the literature.

According to an embodiment, the TS is a sesquiterpene synthase. Any sesquiterpene synthase is suitable for the purpose of the present invention, as these enzymes often catalyse a series of reactions leading to a specific sesquiterpene.

Amongst the large number of known sesquiterpenes, one can differentiate different classes according to the intermediate carbocation of the diphosphate precursor before obtention of the final sesquiterpene. For example, TS include enzymes forming the trans-humulyl cation to synthetise β-caryophyllene and α-humulene, amongst others. Other TSS form the intermediate E,E-germacadienyl cation to obtain germacrene A, B, C, D, valencene, aristolochene, vetiaipinadiene, for example. Of course many other TS are known and can be employed for the purpose of the present invention.

In a preferred embodiment, the TS is a sesquiterpene synthase selected from the group consisting of a patchoulol syn-
thase, valencene synthase, and a cubebol synthase. Alternatively, the TS is a γ-curcumene, (−)-germacrene D, (−)-germacrene D, bicyclo-germacrene, cubebol and/or 6-cadiene synthase. Genes encoding such synthases have been disclosed in the international applications PCT/IB/2004/003836 and WO 2004/031376.

The above examples represent only very few, arbitrarily selected examples of the large number of published sequences suitable for the purpose of providing a sequence encoding a PRT or a TS for the present invention. Accordingly, these few examples of different TSs and PRTs suitably illustrate the wide applicability of the terpene production platform of the present invention, according to which a suitable way for producing any terpene at the discretion of the skilled person is provided.

Preferably, the structural genes in the plant of the present invention provide a functional FPS and a functional TS.

The gene encoding the PRT and/or the TS may be isolated from the plant to be transformed itself. In this case, the transformation of the plant results in additional copies of genes encoding the PRT and/or TS in the transformed plant. Preferably, however, the FPS and/or the TS are heterologously expressed enzymes in the transformed plant.

Preferably, the genes comprising a nucleotide sequence encoding a TS and/or a PRT are transgenes.

In a preferred embodiment, the transformed plant of the present invention accumulates at least 1.5 as much of a specific terpene that can be synthesized by the TS if compared to a native, untransformed plant. Preferably, the transformed plant accumulates at least twice, three times, more preferably at least four times and most preferably at least 6 times as much of the specific terpene.

According to another embodiment of the invention, the transformed plant accumulates at least 1000 ng (nanograms) per g of fresh leaf of a specific terpene that can be synthesized by the TS. Preferably, the transformed plant accumulates at least 1000 ng, more preferably at least 4000 ng, even more preferably at least 5000 ng, still more preferably at least 7000 ng of the specific terpene that can be synthesized by the recombinant TS present in the transformed plant. According to a preferred embodiment, the transformed plant accumulates at least 10000 ng/g of a terpene, preferably a sesquiterpene, that can be synthesized by the TS. Preferably, the transformed plant accumulates at least 13,000 ng, more preferably at least 20,000 ng, even more preferably at least 25,000 ng and most preferably more than 30,000 ng of the specific terpene per g of fresh leaf. The quantity of the specific terpene may also be expressed in weight of dry matter. In this case, dry matter plant material, and in particular leaves, corresponds to about 10% of the values for fresh weight. Accordingly, at least 10, 40, 50, 70, 100, 130, 200, 250, 300 µg terpene per g of dry leaf are accumulated.

In case the native, untransformed plant already produces the specific terpene, the above values valid for the transformed plant are added to the amount of the specific terpene natively present in the untransformed plant.

For determination of the content of the specific terpene in the plant of the present invention, any plant organ producing or accumulating terpenes may be taken as a reference. Preferably, green leaves having the same age are taken from the transformed and non-transformed plant, respectively, for comparison. In general, adult leaves are taken. The analysis is preferably conducted according to the protocol “Terpene analysis” outlined in the examples. Preferably, fresh leaves are analysed directly after cutting from the plant. Leaves may be frozen after harvesting and be analysed in the frozen state.

According to a preferred embodiment, the transformed plant according to the invention is the transformed Nicotiana tabacum. Seeds of the plant of the present invention have been deposited at the ATCC, 10801 University Blvd, Manassas, Va. 20110-2209, USA, under the depositor’s sample references “tpPTs+tpFPS-4” and “p3BpPTS+tpFPS-4” and the Patent Deposit Designations ATCC PTA-6659 and PTA-6660, respectively.

Preferably, the transformed plants may comprise knockout, deletion or other forms of deleterious mutations in selected wild-type genes participating to the terpene biosynthetic pathways suitable to deviate the carbon flux away from the TS of the present invention. For example, the plants of the present invention may have one or more non-functional genes downstream the IPP, GPP and/or GGPP synthases encoding genes leading to the synthesis of sterols, polyenoids, phyto-estrogens and carotenoids. In this way, carbon-flux may more efficiently be directed towards the synthesis of the specific terpene.

The present invention provides for methods of altering and/or increasing the content of specific terpenes in a plant, said methods including a step of transforming plant material with at least one DNA construct comprising structural genes targeted to the plastids of the plant.

Generally, any method for transforming plants with the structural genes of the present invention may be employed. For example, plant cells that have been stripped of their protective cell walls take up pure DNA when treated with certain membrane-active agents or with electroporation. DNA can also be microinjected into target plant cells using very thin glass needles. A recently developed method of plant transformation, biolistics, involves accelerating very small particles of tungsten or gold coated with DNA into cells using an electrostatic pulse, air pressure, or gunpowder percussion.

For example, the structural genes may be directly engineered into the plastid, preferably along with a suitable plastid expression vector. Suitable methods for transforming the plastid genome of plants are disclosed in Lutz K.A., Comelle S, Athagirri A. K., Svb Z., Maligna P. (2004) A novel approach to plastid transformation utilizes the phiC31 phage integrase. Plant journal 37: 906-913.

Accordingly, the present invention provides, in a preferred embodiment, plants in which the structural genes encoding a PRT and a TS are present within the plastid genome and are operatively linked to a plastid expression promoter.

Alternatively, the gene products may be targeted to the plastids by transforming plant material on the level of its nuclear DNA. Accordingly, the invention provides, in a preferred embodiment, plants in which the structural genes comprising nucleotide sequences encoding a PRT and a TS are nuclear genes and comprise, linked to the nucleotide sequence encoding a PRT and/or a TS, a plastid targeting sequence.

According to a preferred embodiment of the invention, the terpene, preferably the sesquiterpene, is, at least in part bio-synthesised via the MEP pathway. Preferably, at least 30% of the terpene that can be synthesised by the terpene synthase is bio-synthesised via the MEP pathway. Preferably, at least 50%, more preferably at least 60% and most preferably at least 80% are obtained through the MEP pathway. The MEP pathway generally uses glyceraldehyde and pyruvate as substrates for synthesising isopentenyl-diphosphate. This pathway is characterized by the intermediate 2-C-methyl-D-erythritol-4-phosphate. It generally takes place in the plastids. A further pathway for IPP, the MVA pathway, generally takes place in the cytosol.
In IPP synthesised by the MEP pathway, carbons of the IPP are differently arranged than if IPP was synthesised through the MEV pathway, resulting in a different arrangement of carbon atoms in the resulting terpene. The different way of arranging carbons in the MEP and the MVA pathways can be utilised for identifying the bio-synthetic origin of a terpene in labelling experiments. For example, incorporation of $[1^{-13}C]$-glucose by the MEP pathway results in IPP having 2 $^{13}C$-labelled carbon atoms, whereas 3 such atoms should be present in IPP resulting from the MVA pathway.

The present inventors have obtained good results with the Agrobacterium tumefaciens-mediated transformation. Preferably, plasmid constructs (vectors) comprising at least one of the structural genes of the present invention, flanked by nucleotide sequences that allow integration of the structural genes into the plant nuclear chromosome DNA are used.

An aspect of the present invention provides a vector comprising a nucleotide sequence encoding a PRT and/or a TS, or a fusion protein of a PRT and a TS, said structural gene further comprising a plastid targeting sequence up-stream or downstream the sequence encoding a PRT, TS or fusion protein. In other words, the vector may comprise only one or both of a nucleotide sequence encoding a PRT and a TS, or a nucleotide sequence encoding a fusion protein of both.

Suitable plastid targeting sequences include sequences encoding a plastid or chloroplast transit peptide. Plastid targeting sequences are known to the skilled person and can be linked in frame to the nucleotide sequence encoding the PRT and/or the TS. One out of many possible examples of available plastid targeting sequences are the Arabidopsis thaliana Rubisco small unit gene (GenBank accession no. NM123102).

Preferably, the plastid targeting sequence is situated at the N-terminal end of the structural gene encoding a PRT and/or TS.

Preferably, the vector further comprises promoter and terminator sequences, preferably up-stream and downstream the nucleotide sequence including the plastid targeting sequence and the structural gene for the PRT and/or TS, respectively. Preferably, the vector comprises strong constitutive promoters. Examples for promoters are the MOS and NOS promoter. Preferably, the promoters are selected to be independent from control and/or feed back regulation mechanisms of the untransformed host plant. Preferably, the recombinant PRT and TS have up-stream promoter sequences. More preferably, they have each different promoter sequences.

Optionally, the vector may further comprise tags suitable for antibody binding, such as His-tags and/or myc tags.

Preferably, the vector of the present invention further comprises a marker suitable for selecting transformed plants. For example, the vector may comprise genes conferring a hygromycin or a kanamycin resistance, or any other kind of marker suitable to select for successfully transformed plants.

Preferably, the vector of the present invention further comprises a left and a right border region, flanking the PRT and/ or TS including optional promoter, terminator, tagging and/or plastid targeting sequences, as well as plant resistance markers, in order to facilitate integration of the structural genes into the plant nuclear genome.

Accordingly, the vector of the present invention preferably comprises structural genes encoding a PRT and/or a TS, linked to at least one plastid targeting sequence, and a marker for selection of transformed plants, flanked by left and right border regions facilitating insertion into the plant genome.

Preferably, the vector further comprises, outside the left and right border region, a marker for selecting positive bacterial transformants used to clone bacteria comprising the vector or used for transformation of plants (Agrobacterium). Transformation of plant material with a DNA construct comprising structural genes targeted to the plastids of the plant may be performed by standard methods, see Schardl et al. Gene (1987) 58: 61; 1-11; Berger et al., Proc Natl Acad Sci USA (1989) 86: 8402-8406; and Horsch et al., Science (1985) 27: 1229-1231. The latter method describing the "leaf disk method", which is particularly suitable for transforming Nicotiana tabacum.

The methods of the present invention further comprise the step of regenerating the transformed plant from the transformed plant material. Methods for regenerating entire plants from transformed plant material are routinely applied by the skilled person. For example, the method disclosed by Horsch et al. (1985) may be employed. In general, segments of leaves comprising transformed cells may be grown in selective media until callus and regenerated plant shoots are evident. Shoots of 1-3 cm in size may be transferred to T-Media (Schardl, 1987) containing antibiotics to stimulate root development. Once root systems are established, the plantlets may be transferred to commercially available potting soil and propagated in a greenhouse.

The present invention further comprises a method for altering the content of specific terpenes produced in a plant, the method comprising the steps of transforming a first plant material with a nucleic acid encoding PRT, transforming a second plant material with a nucleic acid encoding a TS, regenerating a first and a second plant from the first and the second transformed plant material, respectively, crossing the first and the second plant, and, selecting from progeny obtained by the crossing for plants over-expressing both, the recombinant PRT and the recombinant TS.

The above method is a variant method for obtaining the transformed plant of the invention, in that different plant material is separately transformed with a structural gene encoding a PRT or a TS, and transformed plants are regenerated comprising only one of the two recombinant genes.

In a following step, sexually derived progeny is obtained from crossing plants containing recombinant PRT DNA with plants comprising recombinant TS DNA. Preferably, crossing refers to genetic, also called Mendelian crossing. This may typically be done by cross-pollinating. Among the progeny, individuals expressing both, the recombinant PRT as well as the TS are selected.

The present invention further provides a method for producing a specific terpene, the method comprising the step of isolating the terpene from the transformed plant of the invention. The transformed plant may be cultivated and harvested, preferably in sufficiently high amount to render the process economically favourable. The specific terpenes of the invention may be isolated by any method used in the art including but not limited to chromatography, for example gas chromatography (GC) extraction and distillation.

Unless defined otherwise, all chemical and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice of the present invention, exemplary methods and materials are described for illustrative purposes. All publications mentioned in this application are incorporated by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
The following examples are intended to illustrate the invention without limiting the scope as a result. Methods and protocols of the examples are generally performed following standard protocols supplied by the manufacturer of specific materials or kits, or by following well-established protocols defined by Sambrook et al. (1989) and Ausubel et al. (1987).

The attached sequence listings include nucleic acid sequences encoding sequiipetipeptide synthases and an avian farnesyl diphthosphate synthase, coupled to transit peptide sequences.

The nucleotide sequence encoding a patchoulol synthase (bp187-bp1845) linked via a linker sequence to a plastid targeting sequence (bp1-bp171) is named tpPTS (SEQ. ID. NO:1).

The nucleotide sequence encoding an avian farnesyl diphthosphate synthase synthase (bp211-bp1314) linked via a linker sequence to a plastid targeting sequence (bp1-bp171) is named tpFPS (SEQ. ID. NO:2).

The nucleotide sequence encoding a fusion protein in which a PTS encoding region (bp1321-bp2979) is fused to an avian FPS-encoding region (bp211-bp1311) avian farnesyl diphthosphate synthase and further linked via a linker sequence to a plastid targeting sequence (bp1-bp171) is named tpFPS-PTS (SEQ. ID. NO:3).

The nucleotide sequence encoding a amorph-4,11-diene synthase (bp181-bp1821) linked via a linker sequence to a plastid targeting sequence (bp1-bp171) is named tpADS (SEQ. ID. NO:4).

Primers used in the PCR reactions described in the examples are listed under SEQ. ID. NO. 5-70.

Peptide fragments used for preparing antibodies for western blotting are listed under SEQ. ID. NO. 71-78.

For some method or protocol steps, reference is made to the literature, which is listed further below in more detail.

The plant material used to produce plants having their nuclear DNA transformed are Nicotiana tabacum L. cv. Xanthi. Plants having their plastidic DNA transformed are Nicotiana tabacco L.A03.

Examples 1-5

Construction of Recombination and Plant Transformation Vectors

The hygromycin selection marker (Hajdruikiewicz et al., 1994) was chosen for creating a selection marker for transformed plants. New vectors were engineered with appropriate recombination cloning sites as described by Hartley et al. (2000).

Example 1

Development of the pBDON Vector (FIGS. 8 and 11)

The pBI101 vector (Invitrogen, Carlsbad, Calif.) was digested with the restriction enzymes SpI1 and SstI and the DNA fragment corresponding to the plasmid vector (not including the RB border and NPTII gene cassette) was isolated by agarose gel purification (Sambrook et al., 1989) (13). In parallel, an attp recombination cassette including the ccdB gene and chloramphenical resistance gene was amplified from the pDON221 vector (Invitrogen, Carlsbad, Calif.) using standard PCR conditions with primers Attp1-SstI-FW and Attp2-SphI-R. The PCR amplified DNA fragment was restricted with the SphI/SstI enzymes, gel purified and ligated into the corresponding sites of the similarly digested pBI101 vector described above to yield the intermediate pBattp vector (14).

A hygromycin gene cassette was prepared in a 2-step process. First, the hygromycin gene and CaUTR (termination sequence) was PCR amplified from the pCAMBIA1301 (Cambia, Can berra, AU) vector using the PCR primers HPT-NotI-FD and HPT-XbaI-RV, and T/A cloned (Taq-Amplified PCR products directly from the PCR reaction mix) into the p17Blue vector (Novagen, Madison, Wis.) to yield pHPT (15). The right border (RB) and the NOS-promoter (P-NOS) regions were amplified from pBI101 using the PCR primers TB-SphI-FD and TB-NotI-RV (16), then T/A cloned into the p17Blue vector giving rise to vector pTRBP (17). The hygromycin resistance gene cassette was released from vector pTHPT via digestion with NotI/XbaI (18), and cloned into the similarly digested pTRBP vector, resulting in vector pTRBP-PHPPT (19). The NOS promoter-hygromycin-CaUTR cassette was then amplified from this vector using the primers TB-SphI-FD and HPT-SphI-R (20). The amplified product was digested with Sphl and ligated into the corresponding site of pBattp, yielding the pBDON vector (21). The pBDON Ti-vector (FIG. 8) contains an NPTII selection marker outside the T-DNA region for selection in bacteria and the hygromycin gene (HPT) for plant transformation selection. The embedded attp cassette hence provides for the easy insertion of target gene constructs flanked with attB sites into the pBDON vector.

Two different attB help vectors with attB sites (FIGS. 9 A and B) were constructed following the protocol given in FIGS. 12 and 13. One for single gene insertion (pTMON, FIG. 9 A) and the other for two target gene insertions into the pBDON vector (pTDUAL, FIG. 9 B).

Example 2

Generation of the pTMON Vector (FIGS. 9A and 12)

The pTMON vector was constructed by first amplifying the cassava mosaic virus promoter from a modified pBI101 vector with a forward PCR primer containing a NdeI restriction site and an attB1 sequence embedded into the primer CSMV-ATTB1-SGFI-FD, and the reverse primer CSMV-ECORI-RV containing an EcoR1 site (22). The PCR fragment was T/A cloned into the pGem-Teasy vector (Promega, Madison, Wis.) (23), then re-isolated as a NdeI/EcoR1 digestion product (24). The isolated digestion product was ligated into the corresponding restriction sites of the pCVS vector, a pET28a derivative harboring a terpene synthase gene ("Gene 1"), to generate pEPCSV (25).

In parallel, the NOS terminator (NOS) sequence of pBI101 was amplified with the forward primer Tnos-Xhol-FW and the reverse primer Tnos-attB2-RV (26), which incorporated an attB2 recombination site downstream of the NOS sequence. The PCR fragment was T/A cloned into the pGEM-Teasy vector, yielding the pETNOS vector (27). An NdeI/XhoI digestion fragment of pEPCSVS was subsequently ligated into the corresponding sites of pETNOS to generate pTMON (28) (FIG. 9 A).

The pTMON vector was constructed for insertion of a single target gene behind a cassava mosaic virus promoter (Pcv) (Frey et al. 2001) and followed by the Nos terminator sequence.

A plastid targeting sequence was engineered into the pTMON vector. Accordingly, the plastid targeting sequence of the Arabidopsis small subunit RUBP carboxylase/oxygenase gene (GenBank accession NM123202) was amplified
using the primers TP-ASCf and TP-ASCR, digested with Ascl, and ligated into the corresponding restriction site of the mutated pTMON vector.

Example 3

Generation of the pTDUAL Vector (FIGS. 9 B and 11)

The pTDUAL vector was constructed in a multi-step process (FIG. 13, part I and II). First, the cauliflower mosaic virus promoter (Benfey et al., 1990) was amplified from the pBI121 vector (Invitrogen) using the primers PCamV-XbaI-FW and PCamV-SpeI-RV (29), and TA cloned into the p17Blue vector (30). The promoter element was subsequently released from this vector by digestion with XbaI and SpeI (31). In parallel, another terpene synthase gene (“Gene 2”) was amplified with the primers 7120D-SpeI-FW and 7120D-Kpn1-RV, followed by digestion with SpeI/Kpn1 and ligation into the corresponding site of a p17Blue vector and yielding pTHPO (32). pTHPO was then digested with XbaI/SpeI and the CamV promoter fragment similarly released from pTCPa were ligated together to give pTHP10 (33). In parallel to building pTHPO, the NOS terminator sequence was amplified from the pGTNOS vector with primers Tnos-Kpn1-FW and Tnos-attB2-RV3, TA cloned into the pGem-Teasy vector (34) followed by subsequent re-isolation of the fragment by digestion of the pGTVNOS plasmid with Kpn1 and SacI (25). This fragment was then cloned into the corresponding restriction sites of pTH10 to yield pTHPOT (36) (part I of FIG. 11).

In the final steps of constructing the pTDUAL vector, a fragment of the pTMON vector spanning from the attB1 site to the nos-terminator sequence downstream of the inserted terpene synthase gene was amplified using standard PCR conditions (37). The amplification product was obtained with primers CSmV-attBI-SgfI-FD and Tnos-XbaI-RV, which also engineered terminal Sph1 and Xba1 sites onto the fragment. The PCR fragment was digested and ligated into the corresponding Sph1/Xba1 sites of the p17Blue vector, generating pTPCVST (38). Finally, an Xba1 to Sac1 digestion fragment (39) from pTHPOT was ligated into the corresponding sites of pTPCVST (40) to create the pTDUAL vector, which allows for the insertion of 2 gene sequences downstream of strong, constitutive expression promoters (FIG. 13 part II).

The pTDUAL vector (FIG. 9 B) was designed for the insertion of two genes into transgenic plants. Expression of the first gene is directed by the cassava mosaic virus promoter (Frey et al., 2001), while expression of the second gene is directed by a cauliflower mosaic virus promoter (Benfey et al. 1990).

A plastid targeting sequence was engineered into the pTDUAL vectors as for the pTMON vector. In these cases, the plastid targeting sequence of the Arabidopsis small subunit Rubisco carboxylase/oxygenase gene (GenBank accession M12324) was amplified with the primer pair TP-SpeIFW, TP-SpeIRV, or TP-ASCf, TP-ASCR, then digested with SpeI or Ascl, respectively, before ligating the targeting sequence into the corresponding sites of the pTDUAL vector.

Example 4

Construction of the Patchouliol Synthase (PTS) and Patchoulol Synthase+Farnesyl Diphasphosphate Synthase (FPP) Over-Expression Vectors

Generation of the PTS and PTS+FPP expression vectors were greatly facilitated by the appropriate recombination cloning sites associated with the pTMON, pTDUAL and pBDON vectors (FIG. 14). The PTS (WO 2004/031376) or FPP genes (Tarrish et al., 1994) and plastid targeting sequences were amplified with primer pairs PTS-AsclF and PTS-XhoR, or FPP-SpeIFW and FPP-Kpn1RV, respectively (41), digested with either Ascl/Xho1 or SpeI/Kpn1, then ligated into the corresponding sites of the pTMON (42) or pTDUAL (43) vectors. The PTS-PTS gene fusion was created by amplifying the FPP gene with primers FPP-AsclF and FPP-Ascr, digesting the resulting PCR fragment with Ascl and ligating this fragment into the corresponding Ascl site found 5’ to the PTS gene in the pTMON and pTDUAL vectors. The resulting plasmids were then used to mobilize the corresponding PTS, PTS+FPP and FPP-PTS gene cassettes into the pBDON vector by standard recombination cloning (Hartley et al., 2000) generating a family of Ti-plasmid vectors (FIG. 8).

Example 5

Construction of an Amorpha-4,11-diene Synthase (ADS) and Farnesyl Diphasphosphate Synthase (FPP) Over-Expression Vectors

ADS cDNA (Genbank accession number AF138959) was kindly provided by Dr. Peter Brodelius, Kalmar University, Kalmar Sweden, was PCR amplified using the primers ADS-AsclF and ADS-XhoR, and substitution cloned for the PTS gene in the pTDUAL vector also containing the pTPFS gene. DNA sequence encoding for the Arabidopsis transit peptide found associated with the small unit of ribulose-1,5-bisphosphate carboxylase (Rubis CO, GenBank accession no. NM23202) was PCR amplified with Ascl restriction sites associated with the primers (primer sequences TP-ASCf and TP-AScr), digested with the Ascl restriction enzyme and introduced into the same restriction site 5’ to the ADS cDNA gene, creating pTDUAL vector tpADS+tpFPP. The resulting plasmids was then used to mobilize the corresponding tpADS+tpFPP gene cassette into the pBDON vector by standard recombination cloning (Hartley et al., 2000) generating the corresponding Ti-plasmid vector (FIG. 10B, last construct).

Example 6

Plant Transformation and Regeneration

Individual pBDON vector constructs (FIGS. 10 A and 10 B) were transformed into Agrobacterium tumefaciens strain GV3850 by electroporation (Mersereau et al. 1990) and transformants selected for kanamycin resistance. Selected colonies were verified for the transgene constructs by limited DNA sequencing and subsequently grown in 50 ml of LB media containing 100 mg kanamycin/L. Overnight cultures having an OD 600 equal to 0.6-0.8 were concentrated by centrifugation, resuspended in a 30 ml of fresh LB medium (without antibiotic) and used for inoculation of a leaf explants as described previous (Chappell et al., 1995; Horsel et al., 1985). In brief, leaves from plants grown under sterile conditions were placed into the Agrobacterium cultures, cut into approximate 1 cm segments, and the leaf segments plated on non-selective media plates (Murashige and Skoog, 1962). After 3 days, the leaf explants were transferred to media plates containing 15 µg/ml hygromycin (Invitrogen, Carlsbad, Calif.) and 500 µg/ml cefotaxime (BioWorld, Dublin, Ohio) and subsequently to the same selection media weekly until callus and re-generated plant shoots were evident.
Shoots of 1-3 cm in size were then transferred to T-media (Murashige and Skoog, 1962) (containing the same antibiotics) to stimulate root development. Once root systems were established, the plantlets were transferred to commercially available potting soil and propagated in a greenhouse.

**Example 7**

**Terpene Analysis**

Sesquiterpenes extracted from leaf material of transformed plants obtained in Example 6 were identified and quantified by GC-MS analysis. Frozen leaf samples of 250-500 mg were ground in liquid nitrogen, then extracted with 3 mL of a hexane:ethyl acetate mixture (v/v 85:15) containing 200 ng of α-cedrene as an external internal standard. The extract was partially purified by running the sample over a silica column eluted with the same 85:15 mixture of ethyl acetate:hexane. The eluate was concentrated under a stream of nitrogen to 30 μL before analyzing 1 μL aliquots by GC-MS (Yakuhano S, 2005). Samples were injected onto a Trace GC-MS (ThermoFinnigan, Somerset, N.J.) equipped with a Restec Rx-5 capillary column (30 m × 0.32 mm, 0.25 μm phase thickness) operated in the splitless mode with an injector temperature of 250°C and an initial oven temperature of 70°C, for 1 min, followed by a 4°C per min gradient to 230°C. Mass spectra were recorded at 70 eV, scanning from 35 to 300 atomic mass units, and compared to library standards (NIST library) and authentic standards for verification.

FIG. 1 shows the results of terpene analysis of a control tobacco line (WT) and one transformed with a tpPTS+tpFP gene construct for sesquiterpene content. In FIG. 1, a total ion chromatogram for a transgenic line harboring the tpPTS+tpFP gene construct (A) is compared to that for a control plant (non-transformant) (B). Peaks were identified by comparison of their mass spectra to standards or by spectral matches available in the NIST library. For example, the MS for peak 12 (C) is compared to the MS for authentic patchoulool (D). Other peak identities: 1β-patchoulene; 2β-elemene; 3-α-cedrene (internal standard); 4-caryophyllene; 5-α-guaiene; 6-unknown; 7-α-patchoulene; 8-seychellen; 9-unknown, 10-δ-guaiene; 11-globulol; and 12-patchoulool.

FIG. 2 shows the results of terpene analysis of a control tobacco line (WT) and one transformed with a tpADS+tpFP gene construct for sesquiterpene content. Similar to FIG. 1, a total ion chromatogram of the transgenic line is compared to that for a control plant. The highest peak corresponds to Amorpha-4,11-diene, while the second highest peak is cubenol. The arrow indicates the presence of α-cedrene, which was used as an internal standard.

FIGS. 1 and 2 are the result of a GC-MC analysis and illustrates that plants specifically transformed with plastid targeted genes encoding a specific terpene (patchoulol or amorpha-4,11-diene) synthase of interest and a PRT (farnesyl diphosphate synthase) (A) had an altered terpene content if compared to the wild type (B) and over-accumulated patchoulol and amorpha-4,11-diene, respectively, besides other terpenes synthesized by the same terpene synthase.

FIG. 3 is a quantitative analysis of sesquiterpene (patchoulol) content of plants transformed with different constructs. His PTS refers to plants transformed with recombinant genes encoding a patchoulol synthase (PTS) linked to a His-tag. FPSPPTS refers to a fusion protein of farnesyl diphosphate synthase (FPS) and PTS, and PTS+FPS refers to plants transformed with individual genes encoding PTS and FPS. On the right hand of the graph, similar constructs further linked to at least one plastid targeting sequence (tp) are shown. Wildtype plants did not accumulate any patchoulol nor any of the other sesquiterpenes associated with the transgenic lines (FIG. 1).

Amorpha-4,11-diene accumulation was also quantified in the plants transformed with tpADS+tpFPs and was found to be approximately 30 μg/g FW. More detailed sesquiterpene accumulation of individual transgenic lines are shown in Table 3. Control plants (not shown) did not accumulate any amorpha-4,11-diene.

**TABLE 3**

<table>
<thead>
<tr>
<th>Line</th>
<th>Yield (μg/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>11.47</td>
</tr>
<tr>
<td>2</td>
<td>11.61</td>
</tr>
<tr>
<td>4a</td>
<td>25.41</td>
</tr>
<tr>
<td>5</td>
<td>27.88</td>
</tr>
<tr>
<td>6m</td>
<td>6.38</td>
</tr>
<tr>
<td>8</td>
<td>6.23</td>
</tr>
</tbody>
</table>

**Example 8**

**RNA Extraction and Quantitative RT-PCR Analysis**

The total RNA of each line was isolated from 500 mg of young leaves with Trizol reagent according to the manufacturer (Invitrogen Life Technologies, Carlsbad, Calif.). First-strand cDNA was synthesized in 20 μL reactions with 5 μg of total RNA, 200 ng of oligo(dT)12-16 primer and Reverse Transcriptase (Superscript II, Invitrogen Life Technologies) in reaction buffer and conditions as recommended by the manufacturer. One μL of RNase H was subsequently added to the cDNA preparations and incubated at 37°C for 1 hour to remove complementary RNA.

A quantitative RT-PCR method was used to determine mRNA levels in different transgenic lines. Optimal conditions for linear PCR amplification were determined by varying the amount of added cDNA template and using number of PCR cycles (10, 15, 20, 25 and 30). The primers PPTS-8F and PPTS-160R were used to amplify PTS gene, while FFP-1F and FFP-160R were used for the FPP gene. Another primer pair, RBPCS-FW and RBPCS-RV, was used to amplify the RUBiC CO small subunit gene as an internal standard. Typical PCR conditions consisted of 1× Taq buffer (as supplied by the manufacturer), 1.5 mM MgCl₂, 0.2 mM dNTP mixture, 2 μM of each primers, 1.25 μL cDNA, and 1 unit Taq DNA polymerase in a total of 25 μL mixture. PCR amplifications was carried out for 20 temperature cycles, each consisting of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 60 sec. PCR products were separated by agarose gel electrophoresis, stained with ethidium bromide, and photographed.

The results of the PTS and FPP mRNA analysis is shown in FIG. 4. The figure shows RT-PCR products derived from mRNA isolated from plants transformed with constructs containing a patchoulol synthase (PTS) gene, or a plastid targeted PTS (tpPTS) gene, or a construct containing a patchoulol synthase and a FPP gene (PTS+FPS), or a construct containing distinct genes for a plastid targeted PTS and FPP (tpPTS+tpFPs), or a construct encoding for a fusion protein of FPP and PTS (FPS-PTS), or a corresponding, plastid targeted fusion protein (tpFPS-PTS). RDCS is the RT-PCR product
derived from the Rubisco small subunit mRNA, present in the wild-type (WT) and transgenic plants, and serves as an internal standard.

It can be seen that wild-type (WT) plants did not express PFS or FP5. Many of the lines harboring the his PT5, PTS+ FPS, PTS-FPS, and tspPTS constructs expressed readily detectable levels of the PFS mRNA, but patchoulo accumulation was relatively modest and poorly correlated with the PFS mRNA expression levels. In contrast, expression of the plastid targeted tspPTS gene in combination with tspFPS, either as separate genes or as a fusion gene, resulted in similar expression levels of the PFS mRNA and yielded accumulation of significantly higher levels of patchoulo.

Example 9

Protein Expression Analysis

A mixture of 4 to 5 synthesized peptides was used as antigens to prepare antibodies of PFS and FPS. The antigenic peptides were predicted by a free software (http://bioinfo.harvard.edu/Tools/antigenic.html) and selected by direct 3D structural analysis (PDB: 1FPS) for FPS or homology model comparison with an available structure EAS (PDB: 5EAS) for PTS. We designed 5 antigenic peptides (PTS46; PTS108; PTS353; PTS462; PTS475) for PFS, and 4 antigenic peptides (FPF44; FPF59; FPF218; FPF350) for FPS. All the peptides were synthesized in a 10 mg scale at immunological grade by Sigma-Genosys (The Woodland, Tex., US). Each of the peptide mixtures was then conjugated to KLH (Keyhole Limpet Hemocyanin) carrier protein and injected into rabbits by Strategic Biosolutions (Windham, Me.). Polyclonal antibodies for PTS and FPS were further purified by preparative antigenic affinity column prepared with CNBr-activated sepharose 4B resin coupled with purified PTS or FPS protein according to the manufacturer’s instruction (Amersham Biosciences, Buckinghamshire, England).

To measure PTS and FPS protein levels in transgenic plant material, 100 mg of young leave material was ground in liquid nitrogen, then extracted with 800 μL of 80 mM potassium phosphate (pH 7.0), 10% glycerol, 10 mM sodium metabisulphide, 15 mM MgCl2, 10 mM sodium ascorbate, 1% polyvinylpyrrolidone, and 14 mM o-mercaptoethanol. The crude protein samples were centrifuged at 4°C, for 20 min at full speed in a table top microfuge, and the resulting supernatant used as the protein source. Samples containing 40 μg of supernatant protein was electrophoresed in a 15% SDS-PAGE gel and blotted into a nitrocellulose membrane (Biorad, Hercules, Calif.). Membranes were blocked with standard TWEEN 80% Tris-buffered saline (TTBS) blocking solution containing 5% dried milk before adding the purified PTS or FPS antibody. Membranes were then incubated for 3-7 hrs at room temperature with shaking, washed three times with TTBS, and then incubated with goat peroxidase labeled anti-rabbit IgG (Kirkegaard and Perry Laboratories, Gaithersburg, Md.) in TTBS blocking solution for another 3 hours at room temperature. Chemiluminescent detection of the secondary antibody was performed with an ECL reagent kit according to the manufacturer’s instructions (Amersham Biosciences, Buckinghamshire, England).

Expression levels and processing of the patchoulo synthase (PTS) and farnesyl diphosphate synthase (FPS) proteins in transgenic plants are shown in Fig. 5. The numbers above lanes in Fig. 5 represent independent transgenic plant lines engineered to contain a patchoulo synthase (PTS) gene, or a plastid targeted PTS (tpPTS) gene, or a construct containing a patchoulo synthase and a FPS genes (PTS+FPS), or a construct containing distinct genes for a plastid targeted PTS and FPS (tpPTS+ipFPS), or a construct encoding for a fusion protein of FPS and PTS (FPS-PTS), or a corresponding, plastid targeted fusion protein (tpFPS-PTS). The positive control used are PTS and FPS proteins or the corresponding protein containing an amino-terminal plastid targeting peptide (respectively lines PTS, FPS, tpPTS, tpFPS) purified from bacteria transformed to over-express these proteins. Lane WT1, extract from the leaves of a wild-type plant. Upper panels show membranes probed with the PTS antibodies and the two membranes in the lower part of the figure show membranes probing with the FPS antibodies. It can be seen in Fig. 5 that no protein was immunologically detected in the wild type plants. For most of the transgenic lines analysed, PTS and/or FPS proteins could be detected in the leaf extracts and the expression pattern was generally consistent with the patchoulo accumulation. Interestingly, the apparent molecular weight of the PTS and FPS proteins detected in plants transformed with constructs containing the corresponding genes linked to a plastid targeted sequence (for example the lines 2tpPTS and 2tpPTS+tpFPS), are identical to the molecular weight of the same protein expressed in plants or bacteria without plastid targeting signal (for example PTS, 2PTS or 2PTS+FPS). In addition, expression of the PTS or FPS with plastid targeting peptide in bacteria (which can not cleave the targeting peptide) leads to proteins having clearly a higher molecular weight. These observations show that the chloroplast targeted proteins were effectively processed and thus, that these proteins are actually transported to the plastids.

Example 10

[1-14C]-Glucose Labelling for Showing Pathway

Used for Terpene Synthesis in Plants of the Present Invention

Seeds of 8PTS10 (transgenic plant lines expressing PTS in the cytosol) and 2tpPTS+tpFPS12 (plastidic) were germinated on solid MS medium with the addition of hygromycin (15 mg/l).

For GC-MS analysis, thirty 4-week-old seedlings were subsequently transferred to 25 ml flasks containing 5 ml of liquid MS medium without sucrose and incubated with gentle shaking (125 rpm) in the dark. One day later, 100 mg of [1-13C]-glucose (Sigma) was added into media and plant material collected at daily intervals. For GC analysis, 100 mg samples were extracted as described in Example 7.

For NMR analysis, 1000 seedlings of above two transgenic lines were used, with 100 seedling grown in a 250 ml flask containing 50 ml of liquid MS medium with the addition of 1 g [1-13C]-glucose. All labeled seedlings were collected after one week and extracted as above. Concentrated extracts (3 ml) were then purified by preparative TLC separations using silica TLC plates and hexane:ethylacetate (9:1) as the developing solvent. 250 μg of purified [13C]-labeled patchoulo from line 2tpPTS+tpFPS12 and 500 μg from 8PTS10 were subsequently analyzed by 13C-NMR (750 MHz, CDCl3, by Bob Coates in the Chemistry Department, University of Illinois, Champaign, Ill.). Carbon positions and enantiomers were assigned relative to unlabeled patchoulo purified from control plants.

Fig. 6 shows the predicted 13C labelling patterns in patchoulo synthase from IPP emerging from the MVA and the MEP pathway, respectively, in transgenic seedlings fed on [1-13C]-glucose. Patchoulo synthase from IPP of the MVA pathway is predicted to have 9 13C-carbons at positions 1, 3, 5, 7, 9, 12, 13, 14 and 15, whereas its counterpart from the MEP pathway is expected to have only 6 13C-carbons, namely at positions 2, 6, 8, 12, 13 and 15.

Results of GC-MS analysis are shown in Fig. 7, in which Fig. 7 b shows MS parent ions for patchoulo synthesized by
plants fed $^{13}$C-glucose (control) and Figs. 7 c and d plants fed on $^{13}$C-glucose producing pathool by the (cytosolic) MVA and (plasticid) MEP pathway, respectively. It can be seen that pathool emerging from plants fed on $^{13}$C have heavier ions, with the effect being less pronounced with the plastidic pathool: the mass of the major parent ion is shift from 222 to 225, and a M+8 mass parent ion can be observed when the cytosolic pathway is engineered; and the mass of the major parent ion is shifted to 224 and an M+6 mass parent ion can be observed when the chloroplast pathway is engineered. These observations are consistent with the labelling prediction. Results of NMR-analysis are shown in Table 2 below.

### Table 2

<table>
<thead>
<tr>
<th>Carbon atom</th>
<th>$^{13}$C (ppm)</th>
<th>8PTS-10</th>
<th>2ttPTTS + tppFES-12</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>74.9</td>
<td>13.0</td>
<td>0.0</td>
</tr>
<tr>
<td>2</td>
<td>33.1</td>
<td>3.0</td>
<td>13.8</td>
</tr>
<tr>
<td>3</td>
<td>28.9</td>
<td>21.8</td>
<td>4.2</td>
</tr>
<tr>
<td>4</td>
<td>28.1</td>
<td>2.9</td>
<td>2.7</td>
</tr>
<tr>
<td>5</td>
<td>43.8</td>
<td>19.1</td>
<td>2.4</td>
</tr>
<tr>
<td>6</td>
<td>24.5</td>
<td>22.9</td>
<td>18.4</td>
</tr>
<tr>
<td>7</td>
<td>39.4</td>
<td>19.3</td>
<td>2.7</td>
</tr>
<tr>
<td>8</td>
<td>24.9</td>
<td>2.9</td>
<td>17.3</td>
</tr>
<tr>
<td>9</td>
<td>29.1</td>
<td>17.1</td>
<td>3.6</td>
</tr>
<tr>
<td>10</td>
<td>37.8</td>
<td>1.6</td>
<td>2.0</td>
</tr>
<tr>
<td>11</td>
<td>40.1</td>
<td>4.0</td>
<td>4.0</td>
</tr>
<tr>
<td>12</td>
<td>18.8</td>
<td>22.9</td>
<td>19.1</td>
</tr>
<tr>
<td>13</td>
<td>20.9</td>
<td>20.2</td>
<td>17.9</td>
</tr>
<tr>
<td>14</td>
<td>27.3</td>
<td>22.0</td>
<td>6.1</td>
</tr>
<tr>
<td>15</td>
<td>24.7</td>
<td>15.8</td>
<td>13.8</td>
</tr>
</tbody>
</table>

*signal due to contaminant

In accordance with predicted labelling patterns shown in Fig. 6, Table 2 shows that in pathool from plants having PTS and FPS targeted to the plastids, carbon atoms 2, 6, 8, 12, 13 and 15 are enriched with $^{13}$C. The labelling thus shows that the sesquiterpene is actually synthesised from IPP resulting from the MEP-pathway and hence, in the plastids.

### Example 11

**Plant Plasticid Genomes Transformed with PTS and FPS Genes**

The system of recombination cloning into the plastid genome developed by the Maliga laboratory (Lutz et al. 2004) has been used and modified. We used *Nicotiana tabacum* LA63 as the recipient tobacco host material. LA63 has one attB site integrated in chloroplast genome DNA allowing for foreign DNA insertion into this site. A suitable transformation vector was re-constructed as shown in Fig. 15 I-III. We included an IPTG inducible Prn promoter based on previously published work (Muhlbaier and Koop 2005) for providing for regulated gene expression.

#### 11.1 Construction of the Plastid Transformation Vectors

A universal plastid transformation vector pl. vec (Fig. 15 I-III) was constructed, using the p717Blue (Novagen, Madison, Wis.) vector as the backbone. The p717Blue vector DNA was digested with the HindII restriction enzyme. Following treatment with T4 polymerase and self-ligation, the HindII restriction enzyme site was knocked out and the resulting plasmid designated as Δ7765. A linker consisting of two primers (pl.LinkF and pl.LinkR) were introduced into the EcoRI/KpnI sites of p717Blue to create new multiple cloning sites Sgfl-BamHII-Spel-NotI-Smal. The previous EcoRI site was simultaneously removed by linker designing (the last C for the EcoRI recognition sequence was removed). The generated vector was designated as pl.Link.

The attP recombination site was amplified by primer attP XbaI and Atta-SphI and ligated into the XbaI-SphI sites of pl. Link vector and designated as pLattP.

An attA cassette (including Prn promoter and Trbc l-terminator) was amplified using Primer Prn-XbaI and Trbc l-KpnR and ligated into the pl. attP XbaI-KpnI site to make vector pl. attP-aaA+TatP.

The Prn promoter was amplified a second time with primer Prn-KpnI and Prn-SmaR. After digestion with the corresponding restriction enzymes, this fragment was ligated into the KpnI-Smal sites of pLattP-aaA+TatP to make pl. LattP-aaA+Prn-attTatP.

The lnc repressor gene (lacI) gene was amplified from *E. coli* with primers Lact-SmaF and Lact-SmaR. After digestion with SmaI, this fragment was ligated into the Smal site of pl.LattP-aaA+Prn-TatP to make vector pl.LattP-aaA+LacI.

A new terminator Trbc was amplified from tobacco with primer Trbc l-Spel and Trbc l-NotI. The amplified fragment was digested with SpeI and NotI, and ligated into the vector pl.LattP-aaA+LacI to make pl.LattP-aaA+LacI-Trbc.

Based on the publication of Muhlbaier and Koop (2005), an IPTG inducible primer Prnlac was generated by two successive PCR amplification with Prnlac-SglF as forward primer and Prnlac-R1 as backprimer to construct pl. LattP-aaA+LacI to make universal vector pl. vec (Fig. 15 parts II and III). The GUS gene was amplified from Ti vector of pBI21 with primer GUS-BamF and GUS-SpeR. After digestion with corresponding restriction enzymes, the GUS gene was ligated into the pLvec vector to construct pGUS.

A FPS-AscI-PTS fragment was amplified from pTI/PS+ tptTS construct for nuclear transformation with plasmid FPS-BamF and PTS-SpeB. After digestion with corresponding restriction enzymes, FPS-AscI-PTS was ligated into p. vec to make construct plFPS-PTS.

A Trbc l-Spel-PrnhacI construct was constructed in a T/A helper vector. Trbc was first PCR amplified using Trbc l-AscI and Trbc l-SpeI and TA cloned into the pGem-T E Vector (Promega). To obtain sequence orientation, a clone harboring the Trbc l gene 5' to 3' from the T7 promoter to the SP6 promoter was identified and used for the next ligation. This intermediate vector was designated as pTrbcI. Another gene Prnlac was amplified in a same way as described above by using primers Prnlac-SpeB and Prnlac-R1-SpeB. After digestion with SpeI, PrnlacI was ligated into the SpeI site of pTrbcI. A clone having the correct orientation was identified by strategic restriction enzyme digestion and designated as pTrbcI(SpeI)+Prnlac.

After digestion of pTrbcI(SpeI)+Prnlac with AscI, the Trbc l(SpeI)-Prnlac fragment was ligated into the pLPS-FPS AscI site to make the final construct pFP-SPTS. 11.2 Methods for Plastid Transformation DNA Preparation and Gold Treatment

7.5 mg (sufficient for 9 shots) of 1.0 micron gold particles (Bio-rad, Hercules, Calif.) were first sterilized with 1 ml ethanol. After centrifuging, the ethanol was removed and 111 μl fresh ethanol was added. The gold particles were separated into three equal sized aliquots, each with 55 μl ethanol/gold
mixture. 1.0 ml of sterile water was added to each of the ethanol/gold aliquots. After centrifugation 5 min at 100 rpm, the water/ethanol supernatant was removed and gold particles were ready for DNA coating. Five μl of plasmid DNA (pL-GUS ca. 1 μg/ml), 220 μl stabilized water, 250 μl CaCl2 (2.5M), 100 μl spermidine (1M) were added in order and mixed thoroughly. The DNA/gold mixture was then incubated on ice for 2 min, followed by centrifugation (5 min, 1000 rpm) and removal of the supernatant. The DNA/gold pellet was then rinsed with 600 μl ethanol and resuspended in 36 μl of ethanol and placed on ice for 1 hour before using for coating (bioballistic treatment).

During DNA/gold precipitation on ice, plant materials were prepared. One-month old sterile tobacco leaves of line LA63 were cut and placed on water-wetted filter paper (5 cm i.d.) in a petri dish.

10 μl of ice-treated DNA/gold pellet in ethanol was transferred into micro carriers and shot into the leaf material using a particle delivery system (Gene Gun) (model PDS-1000, Dupont) following manufacturer's instructions.

"Shot" leaf segments were transferred onto T02 medium and incubated in the dark for 24 hrs.

Leaf segments were then cut into smaller pieces and transferred into TOM media containing spectinomycin (500 ng/ml) for callus growth. Leaf segments were transferred to fresh selection plates every 15 days until plant shoots were visible.

Regenerated shoots were transferred to rooting medium with 50% spectinomycin selection.

Regenerated plantlets were assessed for GUS expression or terpene accumulation as described above. For GUS expression testing, the GUS staining methods were used. First, the regenerated leaves or shoots (for GUS construction) were incubated with liquid T02 media containing spectinomycin (500 ng/ml) and also with 1 mM IPTG for induction for 3 days. The induced shoots/leaves were moved into GUS staining solution (50 mM potassium phosphate buffer, 12 mM 2-mecaptoethanol, 0.1% Triton X-100, 500 μg/ml 5-bromo-4-chloro-3-indolyl-b-D-glucuronide (Research Products International Corp., Mt. Prospect, Ill.), 2.5 μM potassium ferriyanide, 2.5 μM potassium ferrocyanide) for another day of incubation, then destained in 70% ethanol.

Positive transformants of the plastidic genome showed blue staining. It was thus shown that plastidic genomic DNA of plants were transformed to harbour heterologous genes encoding a sesquiterpene synthase and a farnesyl diphosphate synthase.

Example 12

Insect Repellent Test

Three healthy leaves of the approximate same developmental age (W 5 cm x L 8 cm) were collected for line 2pTPS+tpFPS-12 and wild type 14-2, then placed within an equal distance of one another (ca. 1 cm) within an enclosed box. Six commercially available hornworms (Manduca sexta) (Carolina Biological Supply Company, Burlington, N.C.), at the second instar stage of development were placed on each leaf evenly so that each hornworm had an equal opportunity to eat the leaf or move to another. The experiment was run for 6 hr before counting the digested leaf areas and recording hornworm numbers on each leaf after migration.

REFERENCES


<210> SEQ ID NO 1
<211> LENGTH: 1845
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Patchoulol synthase cDNA of Pogostemon cablin
 linked to a plastid transit peptide sequence
<400> SEQUENCE: 1
atggtctctc ctagctctc cccggtcttc cotggtacat cccggtcttc gcgcacatgc
60
gtgcctccatt ctaaccggtt gaagctctcc gcgcacattc cccggtcttc gcgcacatgc
120
aagggatcag gacgaaaacc gcaggacgag gaaagatact gttgcaataag gcgggacagt
180
ggcgtctgac gtagttggtc ccaacccttt ctctctctcct tccctctccttc ctctctcctc
240
aactttctttc tttacctcag gacgaggaac gtcggtgtga ctggtctggtc gcgggtctgag
300
gctggagga gacgaggaac gtcggtgtgta acgctctac ccggccccttc gtcggtgtga
360
gcatcaggtc gcgacggagt gacgaggaac gtcggtgtgta acgctctac ccggccccttc
420
gagatcagtt tttggagaga ttcctctctc ctctctctcct tcacaggttc ccggccccttc
480
ecccctcttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
540
cacaggttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
600
tagaattc gacgaggaac gtcggtgtgta acgctctac ccggccccttc gtcggtgtga
660
gcatcaggtc gcgagggcct tcacatcag tgggtggtga ctcgcttttc gcgcacatgc
720
gaatcaggtc gcgagggcct tcacatcag tgggtggtga ctcgcttttc gcgcacatgc
780
gggagtgtt gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
840
gcgggcactg gttggtggtga gtagttggtc ccaacccttt ctctctctcct tcacaggttc ccggccccttc
900
gcgggcactg gttggtggtga gtagttggtc ccaacccttt ctctctctcct tcacaggttc ccggccccttc
960
gcccctgcct cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1020
gaatcaggtc gcgagggcct tcacatcag tgggtggtga ctcgcttttc gcgcacatgc
1080
gaatcaggtc gcgagggcct tcacatcag tgggtggtga ctcgcttttc gcgcacatgc
1140
ttcacaggtc gcgagggcct tcacatcag tgggtggtga ctcgcttttc gcgcacatgc
1200
eaattggttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1260
ccccctcttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1320
tccctctcttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1380
tccctctcttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1440
tttggtccttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1500
tttggtccttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1560
tttggtccttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1620
tttggtccttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1680
tttggtccttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1740
tttggtccttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1800
tttggtccttc cccggtcttc gcgcacatgc gcgcacatgc gcgcacatgc gcgcacatgc
1865
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Farnesyl dipropionate cDNA of Gallus gallus
linked to a plastid transit peptide sequence

<400> SEQUENCE: 2
atgcctcct ctagctctc ctgcggcggc gtgtttcata cccccgctca gcgccaccatg
60
gtgcctccat ctagctctc ctgcggcggc gtgtttcata cccccgctca gcgccaccatg
120
aaggaatca cttccatgc cagagaagggg gccatcagt gcgtacccag gatagtgtatg
180
cagccoccct atcatactaa aagggggcca agtgcataat ttaagttctg tcattgtaag
240
ttccagcgaac cccgggtgag gaaacccagc cccgggtgag gtaaggggag gagggggggg
300
tcgtggggt tctccggcga catgatccgc gatgcaccgc ggggagccac cgggcaccg
360
agaagggtggc aagcgctggc gcgggtggag gagggtggag cagcgctggc cccgggctgg
420
aatgcaaac gcgcgggtgc aggttgtggc gcgtacccag gatagtgtatg gcgtacccag ggcgggctg
480
agggatagcg agacccctgc gcgggtgggt gcgtacccag gggagggcag ccgggggggt
540
gccctctcc cggctgtccg gagaagggag gggagggcggt ggcggcag ccgggggggt
600
tgggtgctg cggggtgctg gggagggcag gggagggcggt ggcggcag ccgggggggt
660
tcctctcttg cggggtgctg gggagggcag gggagggcggt ggcggcag ccgggggggt
720
tcgggtccct caggtggcct gggagggcag gggagggcggt ggcggcag ccgggggggt
780
acagcggccg cggagtggcct gggagggcag gggagggcggt ggcggcag ccgggggggt
840
gtataagcc gctccgctgc gggagggcag gggagggcggt ggcggcag ccgggggggt
900
gtgggatgct caggtgggtc gggagggcag gggagggcggt ggcggcag ccgggggggt
960
aatgcaaac gcgcgggtgc aggttgtggc gcgtacccag gatagtgtatg gcgtacccag ggcgggctg
1020
agggatagcg agacccctgc gcgggtgggt gcgtacccag gggagggcag ccgggggggt
1080
cagctcagcc gcgggtgcctg cggggtgctg gggagggcag gggagggcggt ggcggcag ccgggggggt
1140
agggatagcg agacccctgc gcgggtgcctg cggggtgctg gggagggcag gggagggcggt ggcggcag ccgggggggt
1200
tcgggtccct caggtggcct gggagggcag gggagggcggt ggcggcag ccgggggggt
1260
cggagggag cccccccctg cgcggcagac agatcctgca aacgccagaa atga
1320
<210> SEQ ID NO 3
<211> LENGTH: 2979
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Farnesyl dipropionate synthase (Propostemon cabilin)
and farnesyl dipropionate synthase (Gallus gallus) cDNA including
a plastid transit peptide sequence

<400> SEQUENCE: 3
atgcctcct ctagctctc ctgcggcggc gtgtttcata cccccgctca gcgccaccatg
60
gtgcctccat ctagctctc ctgcggcggc gtgtttcata cccccgctca gcgccaccatg
120
aaggaatca cttccatgc cagagaagggg gccatcagt gcgtacccag gatagtgtatg
180
cagccoccct atcatactaa aagggggcca agtgcataat ttaagttctg tcattgtaag
240
ttccagcgaac cccgggtgag gaaacccagc cccgggtgag gtaaggggag gagggggggg
300
tcgtggggt tctccggcga catgatccgc gatgcaccgc ggggagccac cgggcaccg
360
agaagggtggc aagcgctggc gcgggtggag gagggtggag cagcgctggc cccgggctgg
420
aatgcaaac gcgcgggtgc aggttgtggc gcgtacccag gatagtgtatg gcgtacccag ggcgggctg
480
agggatagcg agacccctgc gcgggtgggt gcgtacccag gggagggcag ccgggggggt
540
gccctctcc cggctgtccg gagaagggag gggagggcggt ggcggcag ccgggggggt
600
tgggtgctg cggggtgctg gggagggcag gggagggcggt ggcggcag ccgggggggt
660
tcctctcttg cggggtgctg gggagggcag gggagggcggt ggcggcag ccgggggggt
720
tcgggtccct caggtggcct gggagggcag gggagggcggt ggcggcag ccgggggggt
780
acagcggccg cggagtggcct gggagggcag gggagggcggt ggcggcag ccgggggggt
840
gtataagcc gctccgctgc gggagggcag gggagggcggt ggcggcag ccgggggggt
900
gtgggatgct caggtgggtc gggagggcag gggagggcggt ggcggcag ccgggggggt
960
aatgcaaac gcgcgggtgc aggttgtggc gcgtacccag gatagtgtatg gcgtacccag ggcgggctg
1020
agggatagcg agacccctgc gcgggtgggt gcgtacccag gggagggcag ccgggggggt
aaggtgtgctg agagctcttgcc gttgocctggct ggcgctggtt ggtgcctgcag gttggtcgcag 540
gcctcttctt tcggtccttg agagatcggc gttggcctgct ggtgcctgcag 550
tgtagagctg atcgctggag cggccttgct gttggcctgca gttggtcgcag 560
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 570
ttggaggcttg ctggcttgctg ctggcttgctg ctggcttgctg ctggcttgctg 580
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 590
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 600

gaaacggggag agagatcggc gttggcctgct ggtgcctgcag 610
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 620

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 630
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 640

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 650
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 660

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 670
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 680

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 690
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 700

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 710
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 720

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 730
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 740

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 750
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 760

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 770
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 780

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 790
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 800

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 810
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 820

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 830
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 840

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 850
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 860

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 870
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 880

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 890
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 900

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 910
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 920

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 930
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 940

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 950
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 960

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 970
ttcctctcttc tcctggccttg agagatcggc gttggcctgct ggtgcctgcag 980

gttgtgccttg agagatcggc gttggcctgct ggtgcctgcag 990
cttgaagcatta tttacaaga gggcgattcg tata cacaca tgggtcttcgg aatgccaaac
atcatacagc agtgtgactct tcaacctggtt ccataa

<210> SEQ ID NO 4
<211> LENGTH: 1821
<212> TYPE: DNA
<213> ORGANISM: Artificial
<215> FEATURE:
<223> OTHER INFORMATION: Amorpho-4,11-diene synthase encoding cDNA of Artemisia annua linked to a plastid transit peptide sequence

<400> SEQUENCE: 4

atggtccctctagacctcttcggccgatcgctggtcagcgggtgaacgggtggtggtacatcgcccgaac

60

gtgccattc tcccgagcctt gaagctcactcg tgtctgttcgc tgtgtacggc ggtgttcctcga
gggtgcggcc cgggacgctc ctttaaagctcctc cttttaaagcc cgggtgcgctg
gggcagtctctgc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc
gggcagtctctgc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc
gggcagtctctgc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc
gggcagtctctgc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc
gggcagtctctgc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc
gggcagtctctgc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc
gggcagtctctgc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc ggtgtgtcagc

1380
ggcggcggc gggcggcggc gggcggcggc gggcggcggc gggcggcggc
ggcggcggc gggcggcggc gggcggcggc gggcggcggc gggcggcggc
ggcggcggc gggcggcggc gggcggcggc gggcggcggc gggcggcggc
ggcggcggc gggcggcggc gggcggcggc gggcggcggc gggcggcggc
ggcggcggc gggcggcggc gggcggcggc gggcggcggc gggcggcggc

1740
gggcggcggc gggcggcggc gggcggcggc gggcggcggc gggcggcggc
gggcggcggc gggcggcggc gggcggcggc gggcggcggc gggcggcggc

1800
gttatccta tggagttagtg

1821
agtcagacgt tgtaataacgg aagggca 27
<210> SEQ ID NO 6
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: AttP1-SstI-FW (Primer)

<400> SEQUENCE: 6
gcatgccagg aacacagtcat gac 23

gggccgccat gaaaagctt gaaactc 26
<210> SEQ ID NO 7
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: HPT-NotI-PD (Primer)

<400> SEQUENCE: 7
tctagataat tcgaggggatc tggat 25

<210> SEQ ID NO 9
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: TB-SphI-PD (Primer)

<400> SEQUENCE: 9
gtggctggca tgcacataca aatgga 26

ggcgcccccg gaaacgatcc agatcc 26
<210> SEQ ID NO 10
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: HPT-SphI-RV (Primer)

<400> SEQUENCE: 10
gggccatgcc aatcggggag atctgga 28
<210> SEQ ID NO 12
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: CSMV-ATTB1-EGFP-FD (Primer)

<400> SEQUENCE: 56
      ggggacagttgtagaaataagccagggctgtgtagccctcatttcataatgaag  56

<210> SEQ ID NO 13
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: CSMV-ECORI-FW (Primer)

<400> SEQUENCE: 31
tacgaatctcaasattttctctgagttgta  31

<210> SEQ ID NO 14
<211> LENGTH: 49
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Thoo-XhoI-FW (Primer)

<400> SEQUENCE: 49
cggatgctgctagatcgctctaacatattggc  49

<210> SEQ ID NO 15
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Thoo-attB2-FV (Primer)

<400> SEQUENCE: 35
ggggaccactttgtagaaataagctggggctgtcattagtaatcagatggc  35

<210> SEQ ID NO 16
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: His-EcoF (Primer)

<400> SEQUENCE: 36
aatccgcccggccatcatcatatccattatcg  36

<210> SEQ ID NO 17
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: mHisPTS-F (Primer)

<400> SEQUENCE: 44
aatcgtgatgtgcagcatgtctaatcgatgatgccg  44
<400> SEQUENCE: 18
cttcagaga atttgtagat tatacatcat ctcacatcatc aecgg 44

<210> SEQ ID NO 19
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: mHiePTS-R (Primer)

<400> SEQUENCE: 19
cgagcgatg gatagatagt tataaattcac aasatctctct gaag 44

<210> SEQ ID NO 20
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: TP-ASCF (Primer)

<400> SEQUENCE: 20
ttgcccgcctc tattgctcttc tctatgctc c 31

<210> SEQ ID NO 21
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: TP-ASCR (Primer)

<400> SEQUENCE: 21
ttgcccgcctc aatacgcttcttc tctatcctc c 31

<210> SEQ ID NO 22
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCaMV-XbaI-PW (Primer)

<400> SEQUENCE: 22
tacgtttcct gacatggagt caagattca a 31

<210> SEQ ID NO 23
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCaMV-SpeI-RV (Primer)

<400> SEQUENCE: 23
acatgacta gttcccgtcg ttcctcctc 27

<210> SEQ ID NO 24
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: 7120D-SpeI-PW (Primer)

<400> SEQUENCE: 24
actagatgc aatcttccag cttggttt 28

<210> SEQ ID NO 25
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: T120D-KpnI-KV (Primer)

<400> SEQUENCE: 25
cggggtacct taccgogaaggttgata agg

<210> SEQ ID NO 26
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Tnco-KpnI-FW (Primer)

<400> SEQUENCE: 26
cggggtaccg atcgctttgta catttggc

<210> SEQ ID NO 27
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Tnco-attB2-KV3 (Primer)

<400> SEQUENCE: 27
gagctctggg accacttttgt a

<210> SEQ ID NO 28
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: CsMV-attB1-Sgf I-FD (Primer)

<400> SEQUENCE: 28
ggggcaagt ttgtaacaag gacagcgctc gctagctttcct atgttccaaa atgaag

<210> SEQ ID NO 29
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: THOS-XbaI-KV (Primer)

<400> SEQUENCE: 29
gctctagaga tctagtaaca tagatgac

<210> SEQ ID NO 30
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: TP-SpeFW (Primer)

<400> SEQUENCE: 30
gggacagt atggttcct ctaggtccc

<210> SEQ ID NO 31
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: TP-SpeRV (Primer)

<400> SEQUENCE: 31
ggggacctg atttcgctag atggaccttc
<210> SEQ ID NO 32
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PTS-AscF (Primer)

<400> SEQUENCE: 32
gagggagtccg ggcgcgcgcg gagggtgtat gcgc 34

<210> SEQ ID NO 33
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PTS-XhoR (Primer)

<400> SEQUENCE: 33
gagggagtccg ttaatatgga acaggtgaa g 31

<210> SEQ ID NO 34
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: FPP-SpeFW (Primer)

<400> SEQUENCE: 35
gggtactgt atgcagccc acatcatca tsag 33

<210> SEQ ID NO 35
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: FPS-AscF (Primer)

<400> SEQUENCE: 36
ttgccgcgcc tattcgagcc catcatc 30

<210> SEQ ID NO 37
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PTS-8F (Primer)

<400> SEQUENCE: 37
ttgccgcgcc tttctgagcc ttgtagatc 30
<400> SEQUENCE: 38
gagtggtgcc tgcctctctg cctc 24

<210> SEQ ID NO: 39
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PTS-160R (Primer)

<400> SEQUENCE: 39
cctcatggac tctgagatgc gtgg 24

<210> SEQ ID NO: 40
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: FPP-1F (Primer)

<400> SEQUENCE: 40
gcagccccat cattcatcata aagagg 26

<210> SEQ ID NO: 41
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: RBCS-FW (Primer)

<400> SEQUENCE: 41
gagatccgca ggaggaagga gtc 23

<210> SEQ ID NO: 42
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: RBCS-RV (Primer)

<400> SEQUENCE: 42
atgcaggtgt ggcaccaat t 21

<210> SEQ ID NO: 43
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: ADG-AncF (Primer)

<400> SEQUENCE: 44
ttgccgcgcc gatgctcactt acagaagaaa aacc 34

<210> SEQ ID NO: 45
<211> LENGTH: 34
<210> SEQ ID NO 46
<211> LENGTH: 46
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: ADS-HhoR (Primer)

<400> SEQUENCE: 46
ggggcttagc tacatatactc ataggataaa gtagc 34
dgtggtggtc ccggggccc gcccggggg tac 43

<210> SEQ ID NO 47
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: pLlinkR (Primer)

<400> SEQUENCE: 47
coccccggccc ggcgcaactc tgaatccgag atccg 35

gctcagaga gcaatccggc tgggtg 26

<210> SEQ ID NO 48
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: attP-XbaF (Primer)

<400> SEQUENCE: 49
ggggcatgc cccgctcaac acccttg 28

gctcagaga agtgtcactc tgaagttg 20

<210> SEQ ID NO 50
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: TrbcL - XpnR (Primer)

<400> SEQUENCE: 51
ggggtaccgt atccggtcata ccttctttag 30
<210> SEQ ID NO 52
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Prn-KpnI (Primer)

<400> SEQUENCE: 52
ggggtaccag agtgtcaacct tgaacgtgc

<210> SEQ ID NO 53
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Prn-SmaR (Primer)

<400> SEQUENCE: 53
tccccgggs aatccotccc tacaactg

<210> SEQ ID NO 54
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Tatp-NotR (Primer)

<400> SEQUENCE: 54
tccccgggs gaaatatgga tcacttttg

<210> SEQ ID NO 55
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: LacI-SmaR (Primer)

<400> SEQUENCE: 55
ggggccggcg ctttaatttc catatatatt t

<210> SEQ ID NO 56
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Trbc1-SpeF (Primer)

<400> SEQUENCE: 56
tccccgggt cactgcgccg tttcagtcg

<210> SEQ ID NO 58
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Trbc1-SpeF (Primer)
<400> SEQUENCE: 58

ggactagtaa aacagtagac attagcagat aa

<210> SEQ ID NO 59
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Tbrcl-NotR (Primer)

<400> SEQUENCE: 59

gggggccggc ggtattcgg ctcacaacctt ttg

<210> SEQ ID NO 60
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PrnLacI-SgfF (Primer)

<400> SEQUENCE: 60

ggggtcgatcg cagaggtgca cctgacggtg gty

<210> SEQ ID NO 61
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PrnLacI-Rinest (Primer)

<400> SEQUENCE: 61

attgcccggc agttcgctcc cagaaatata ttgattcgg ctcacaacctg tcaatcccac

<210> SEQ ID NO 62
<211> LENGTH: 59
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PrnLacI-BamHR (Primer)

<400> SEQUENCE: 62

cggatccaa atccctccct acaactgtat ccaagcggtt cgtattcggc cggagttcgg

<210> SEQ ID NO 63
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: GUS-BamP (Primer)

<400> SEQUENCE: 63

cggatcttc gttaagttgcc tccctgtgcgc

<210> SEQ ID NO 64
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: GUS-SpeR (Primer)

<400> SEQUENCE: 64

ggactagtc attgtttgccc tccctgctgc
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Fps-BamF (Primer)  
<400> SEQUENCE: 65  
eggattcag gcagccocat cactcata aag  

<210> SEQ ID NO: 66  
<211> LENGTH: 29  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Fps-SpeR (Primer)  
<400> SEQUENCE: 66  
ggactagttt aatagtgaac agggtgaag  

<210> SEQ ID NO: 67  
<211> LENGTH: 30  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Trbcl-AacF (Primer)  
<400> SEQUENCE: 67  
ttggcgccc aaaacagtag acattagcag  

<210> SEQ ID NO: 68  
<211> LENGTH: 30  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Trbcl-SpeR (Primer)  
<400> SEQUENCE: 68  
ggactagtgt aagctgctca atccttttag  

<210> SEQ ID NO: 69  
<211> LENGTH: 40  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: FrrnlacI-SpeF (Primer)  
<400> SEQUENCE: 69  
ggactagtga agtgtcacc tgaactggttg  

<210> SEQ ID NO: 70  
<211> LENGTH: 40  
<212> TYPE: DNA  
<213> ORGANISM: Artificial  
<220> FEATURE:  
<223> OTHER INFORMATION: Frrnlac-AacI-SpeR (Primer)  
<400> SEQUENCE: 70  
ggactagtgg cgccgcaaat cctcctac aactgtatcc  

Glu Glu Leu Lys Val Glu Leu
<210> SEQ ID NO 72
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PTS108 antigenic peptide

<400> SEQUENCE: 72
His Ala Thr Ala Leu Ser Phe Arg Leu Leu Arg Gln His Gly Tyr Arg
1      5       10       15
Val Ser Cys Glu
20

<210> SEQ ID NO 73
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PTS353 antigenic peptide

<400> SEQUENCE: 73
His Val Arg Thr Ala Val Glu Cys Tyr Met Glu
1      5       10

<210> SEQ ID NO 74
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PTS462 antigenic peptide

<400> SEQUENCE: 75
Lys Val Gly Lys Gln Glu Val Val Ser Glu
1      5       10

<210> SEQ ID NO 76
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: FPP41 antigenic peptide

<400> SEQUENCE: 76
Glu Phe Val Gly Phe Phe Pro Gln Ile Val Arg
1      5       10
The invention claimed is:

1. A transformed plant accumulating patchoulol, which is transformed to comprise at least one nucleotide sequence encoding a farnesyl diphosphate synthase (FPS) and a patchoulol synthase, both targeted to plant plastids, wherein said nucleotide sequence comprises SEQ ID NO:1 and wherein said transformed plant accumulates at least 10,000 ng/g of fresh leaf of patchoulol.

2. The transformed plant according to claim 1, in which patchoulol is, at least in part, bio-synthesised via the MEP pathway.

3. The transformed plant according to claim 1, in which the FPS is a non-plant prenyl transferase.

4. The transformed plant according to claim 1, in which the at least one nucleotide sequence is integrated into plant plastidic DNA.

5. A vector comprising at least one nucleotide sequence comprising SEQ ID NO:1 and encoding a farnesyl diphosphate synthase (FPS) and a patchoulol synthase, or a fusion protein of a FPS and a patchoulol synthase, with the nucleotide sequence further comprising a plastid targeting sequence linked in frame to the nucleotide sequence encoding the FPS, the patchoulol synthase, or the fusion protein.

6. A method for altering the content of patchoulol in a plant so that said plant accumulates at least 10,000 ng/g of fresh leaf of patchoulol, which comprises: transforming plant material with at least one DNA construct comprising at least one nucleotide sequences encoding a FPS and a patchoulol synthase, targeted to plant plastids, said DNA construct comprising SEQ ID NO:1 and regenerating a transformed plant from the transformed plant material.

7. A method of producing patchoulol which comprises providing a transformed plant according to the method of claim 6 and isolating patchoulol from the transformed plant.

8. A method for producing a plant having an altered patchoulol content and accumulating at least 10,000 ng/g of fresh leaf, which comprises: transforming plant material with at least one DNA construct comprising at least one nucleotide sequences encoding a FPS and a patchoulol synthase, targeted to plant plastids, said DNA construct comprising SEQ ID NO:1 and regenerating a transformed plant from the transformed plant material.

9. A method of producing patchoulol which comprises providing a transformed plant according to the method of claim 8 and isolating patchoulol from the transformed plant.

10. A method of producing patchoulol, which comprises isolating patchoulol from the plant of claim 1.
UNIVERSITRIC PATENT AND TRADMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 8,017,835 B2
APPLICATION NO. : 11/911660
DATED : September 13, 2011
INVENTOR(S) : Chappell et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**Title Page:**
Item (75) Inventors: correct the spelling of the first name of inventor Clark from “Athony” to -- Anthony --. The inventor’s name will then correctly appear as “Anthony Clark”.

Add the following item before Item (30):

-- Related U.S. Application Data

(60) Provisional application no. 60/673,019, filed Apr. 19, 2005 --.

Signed and Sealed this
Twenty-ninth Day of May, 2012

David J. Kappos
Director of the United States Patent and Trademark Office